Research Article Details

Article ID: A18396
PMID: 27161854
Source: Scand J Gastroenterol
Title: Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease.
Abstract: OBJECTIVE: The gold standard for diagnosing fibrosis stage in non-alcoholic fatty liver disease (NAFLD) is liver biopsy. The aim of this study was to determine whether contrast-enhanced ultrasonography (CEUS) with transit time measurements could be a non-invasive alternative for differentiating none or mild from severe fibrosis in NAFLD patients. Various serum markers and clinical variables were also evaluated. MATERIALS AND METHODS: Fifty-eight patients with NAFLD underwent CEUS prior to liver biopsy. All patients were also evaluated according to the G&#246;teborg University Cirrhosis Index (GUCI), the AST-Platelet Ratio Index (APRI), the NAFLD fibrosis score, and the FIB-4 and BARD score. RESULTS: The hepatic vein arrival time (HV) was shorter in patients with severe fibrosis (25.9&#8201;&#177;&#8201;4.8 vs 29.5&#8201;&#177;&#8201;4.7&#8201;s, p&#8201;=&#8201;0.023), and the difference between the hepatic and portal vein (&#916;HV-PV) was shorter (2.3&#8201;&#177;&#8201;2.8 vs 6.4&#8201;&#177;&#8201;2.8&#8201;s, p&#8201;<&#8201;0.0001) while the difference in arrival time between the portal vein and hepatic artery (&#916;PV-HA) arrival time was significantly longer (6.0&#8201;&#177;&#8201;2.2 vs 3.6&#8201;&#177;&#8201;1.6&#8201;s, p&#8201;<&#8201;0.0001). The area under receiver operating characteristics curve values for HV, &#916;HV-PV and &#916;PV-HA to separate none or mild from severe fibrosis was 0.71, 0.83 and 0.84, respectively. The corresponding figures for GUCI, APRI, NAFLD fibrosis score, FIB-4 and BARD score were 0.93, 0.92, 0.86, 0.90 and 0.77, respectively. CONCLUSIONS: CEUS and non-invasive scoring systems could exclude severe fibrosis in NAFLD patients.
DOI: 10.3109/00365521.2016.1172336